CC Quote, Financials, Valuation and Earnings

Dow has a net margin of -0.29% compared to The Chemours's net margin of -2.94%. The Chemours's return on equity of 4.67% beat Dow's return on equity of 1.6%.

The Chemours has a consensus price target of $15.11, signalling upside risk potential of 14.05%. On the other hand Dow has an analysts' consensus of $34.18 which suggests that it could grow by 21.48%. Given that Dow has higher upside potential than The Chemours, analysts believe Dow is more attractive than The Chemours.

The Chemours has a beta of 1.652, which suggesting that the stock is 65.152% more volatile than S&P 500. In comparison Dow has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.13%.

The Chemours has a quarterly dividend of $0.09 per share corresponding to a yield of 6.32%. Dow offers a yield of 9.95% to investors and pays a quarterly dividend of $0.70 per share. The Chemours pays 172.09% of its earnings as a dividend. Dow pays out 176.17% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

The Chemours quarterly revenues are $1.4B, which are smaller than Dow quarterly revenues of $10.4B. The Chemours's net income of -$4M is higher than Dow's net income of -$307M. Notably, The Chemours's price-to-earnings ratio is 69.74x while Dow's PE ratio is 70.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours is 0.34x versus 0.47x for Dow. Usually stocks with elevated PS ratios are considered overvalued.

Huntsman has a net margin of -0.29% compared to The Chemours's net margin of -0.36%. The Chemours's return on equity of 4.67% beat Huntsman's return on equity of -4.78%.

The Chemours has a consensus price target of $15.11, signalling upside risk potential of 14.05%. On the other hand Huntsman has an analysts' consensus of $13.12 which suggests that it could grow by 16.07%. Given that Huntsman has higher upside potential than The Chemours, analysts believe Huntsman is more attractive than The Chemours.

The Chemours has a beta of 1.652, which suggesting that the stock is 65.152% more volatile than S&P 500. In comparison Huntsman has a beta of 0.706, suggesting its less volatile than the S&P 500 by 29.382%.

The Chemours has a quarterly dividend of $0.09 per share corresponding to a yield of 6.32%. Huntsman offers a yield of 8.85% to investors and pays a quarterly dividend of $0.25 per share. The Chemours pays 172.09% of its earnings as a dividend. Huntsman pays out -92.06% of its earnings as a dividend.

The Chemours quarterly revenues are $1.4B, which are smaller than Huntsman quarterly revenues of $1.4B. The Chemours's net income of -$4M is higher than Huntsman's net income of -$5M. Notably, The Chemours's price-to-earnings ratio is 69.74x while Huntsman's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours is 0.34x versus 0.33x for Huntsman. Usually stocks with elevated PS ratios are considered overvalued.

Innospec has a net margin of -0.29% compared to The Chemours's net margin of 7.44%. The Chemours's return on equity of 4.67% beat Innospec's return on equity of 2.21%.

The Chemours has a consensus price target of $15.11, signalling upside risk potential of 14.05%. On the other hand Innospec has an analysts' consensus of $115.00 which suggests that it could grow by 36.05%. Given that Innospec has higher upside potential than The Chemours, analysts believe Innospec is more attractive than The Chemours.

The Chemours has a beta of 1.652, which suggesting that the stock is 65.152% more volatile than S&P 500. In comparison Innospec has a beta of 1.047, suggesting its more volatile than the S&P 500 by 4.676%.

The Chemours has a quarterly dividend of $0.09 per share corresponding to a yield of 6.32%. Innospec offers a yield of 1.93% to investors and pays a quarterly dividend of $0.84 per share. The Chemours pays 172.09% of its earnings as a dividend. Innospec pays out 108.99% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

The Chemours quarterly revenues are $1.4B, which are larger than Innospec quarterly revenues of $440.8M. The Chemours's net income of -$4M is lower than Innospec's net income of $32.8M. Notably, The Chemours's price-to-earnings ratio is 69.74x while Innospec's PE ratio is 79.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours is 0.34x versus 1.19x for Innospec. Usually stocks with elevated PS ratios are considered overvalued.

Koppers Holdings has a net margin of -0.29% compared to The Chemours's net margin of -3.05%. The Chemours's return on equity of 4.67% beat Koppers Holdings's return on equity of 5.01%.

The Chemours has a consensus price target of $15.11, signalling upside risk potential of 14.05%. On the other hand Koppers Holdings has an analysts' consensus of $59.50 which suggests that it could grow by 83.42%. Given that Koppers Holdings has higher upside potential than The Chemours, analysts believe Koppers Holdings is more attractive than The Chemours.

The Chemours has a beta of 1.652, which suggesting that the stock is 65.152% more volatile than S&P 500. In comparison Koppers Holdings has a beta of 1.486, suggesting its more volatile than the S&P 500 by 48.637%.

The Chemours has a quarterly dividend of $0.09 per share corresponding to a yield of 6.32%. Koppers Holdings offers a yield of 0.93% to investors and pays a quarterly dividend of $0.08 per share. The Chemours pays 172.09% of its earnings as a dividend. Koppers Holdings pays out 11.26% of its earnings as a dividend. Koppers Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but The Chemours's is not.

The Chemours quarterly revenues are $1.4B, which are larger than Koppers Holdings quarterly revenues of $456.5M. The Chemours's net income of -$4M is higher than Koppers Holdings's net income of -$13.9M. Notably, The Chemours's price-to-earnings ratio is 69.74x while Koppers Holdings's PE ratio is 27.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours is 0.34x versus 0.33x for Koppers Holdings. Usually stocks with elevated PS ratios are considered overvalued.